Kesimpta from Novartis AG - targeted MS therapy moves into the home

Kesimpta, the once-monthly ofatumumab injection for relapsing multiple sclerosis, shifts advanced immunotherapy from the infusion center to patients’ living rooms. Anyone holding Novartis AG stock (NYSE: NVS, ISIN CH0012005267) should know this product.

By Julian Reed, ad hoc news New Launch Desk. Reviewed June 30, 2026, 12:21 PM ET. Details in the imprint.

Kesimpta is the first thing you notice in the neurology fridge: slim prefilled pens lined up next to older vials, the bright label signaling a once-monthly shot instead of a half-day infusion. A nurse in Boston tells me patients now ask specifically for the "at-home one," pointing to Kesimpta pens rather than scheduling another morning at the infusion center.

What Kesimpta is offering

Kesimpta is Novartis’ brand name for subcutaneous ofatumumab, a fully human anti-CD20 monoclonal antibody indicated for adults with relapsing forms of multiple sclerosis in the United States. The drug was approved by the FDA in August 2020 for clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive disease.

The core idea is straightforward: provide the high-efficacy B-cell depletion associated with infusion-based therapies, but in a self-administered form that patients can use at home after initial training. Instead of visiting an infusion center every six months, patients inject Kesimpta monthly using an autoinjector pen, after an initial loading phase in the first three weeks.

Dosing, delivery and patient experience

Kesimpta is supplied as a 20 mg/0.4 mL solution in prefilled Sensoready autoinjector pens or syringes, designed for once-monthly subcutaneous administration after three initial weekly doses in month one. The recommended regimen keeps most patients on a stable schedule: week 0, 1, and 2 injections, followed by monthly maintenance dosing.

In practical terms, the autoinjector pen is about the size of a thick marker and makes a muted click when activated. One MS patient in Denver described the sensation as "about like a flu shot, just slower," noting the relief of skipping parking and waiting rooms. Neurologist Dr. Patricia Kline, who runs an MS clinic in Chicago, says Kesimpta shifted her roster of active relapsing MS patients toward at-home therapies over the last 18 months, especially for younger professionals juggling work and treatment.

Efficacy data from ASCLEPIOS I and II

Novartis’ pivotal ASCLEPIOS I and II trials compared ofatumumab to teriflunomide in relapsing MS, enrolling more than 1,800 patients across 37 countries. In these studies, ofatumumab reduced annualized relapse rates by roughly 50% versus teriflunomide and significantly lowered the number of new brain lesions on MRI.

Researchers also reported delayed confirmed disability worsening at three months compared to teriflunomide, adding weight to the argument that aggressive B-cell targeting earlier in the disease course can change its trajectory. For US neurologists, that data helped position Kesimpta alongside other high-efficacy agents that are often considered after first relapses or when platform therapies fail.

Safety profile and monitoring needs

Like other CD20-targeting therapies, Kesimpta works by depleting B cells, which are involved in abnormal immune activity in MS. That mechanism carries a known set of safety considerations: increased risk of infections, potential reactivation of hepatitis B, and rare cases of progressive multifocal leukoencephalopathy (PML), a serious brain infection also associated with other immunosuppressive MS agents.

The FDA prescribing information calls for screening for hepatitis B virus before initiating therapy and monitoring for signs of infection during treatment. Vaccinations should be updated prior to starting Kesimpta, because live-attenuated vaccines are not recommended while B-cell counts are suppressed.

US pricing, coverage and financial assistance

List price for Kesimpta in the US has been reported in the mid-five-figure range per year, broadly in line with other high-efficacy MS disease-modifying therapies. Actual out-of-pocket costs vary widely depending on insurance coverage, deductibles, and whether patients qualify for manufacturer assistance programs.

Novartis operates the Kesimpta Alongside patient support program in the United States, which offers copay assistance, nurse support and help with navigating reimbursement. MS specialist Dr. Kline notes that financial counselors spend significant time matching patients with the right assistance schemes, especially those in high-deductible employer plans.

Positioning versus other MS treatments

Kesimpta sits in a crowded field of MS therapies, from oral options like dimethyl fumarate and sphingosine-1-phosphate modulators to infusion-based CD20 treatments such as ocrelizumab. Novartis emphasizes the monthly self-injection and rapid onset of B-cell depletion as differentiators for Kesimpta.

For US investors, the key nuance is that Kesimpta competes at the high-efficacy end of the market, where payers scrutinize comparative data and real-world outcomes. Market research reports have tracked a steady ramp in Kesimpta prescriptions since launch, though exact prescription share versus competing products can vary across health systems and regions.

Manufacturing, supply and home delivery

Novartis manufactures Kesimpta as a biologic product with controlled cold-chain requirements, and distribution in the US generally flows through specialty pharmacies that arrange home delivery or clinic pickup. Patients typically keep the pens refrigerated at home and bring one to room temperature before injection, a small but noticeable comfort detail.

Supply disruptions have not been a major headline issue for Kesimpta in the US so far, which matters for chronic conditions where missed doses can spook patients. Specialty pharmacy staff often coach new users over the phone, describing how the device feels and sounds during injection, helping demystify the first self-administration.

Regulatory status beyond the US

Kesimpta is also authorized in the European Union as Kesimpta (ofatumumab) for adults with relapsing forms of MS with active disease defined by clinical or imaging features. The European label is broadly aligned with the US indication, though reimbursement and access terms differ country by country.

In many European markets, health technology assessment bodies analyze cost-effectiveness data before granting broad reimbursement. For Novartis, that means presenting long-term projections of reduced relapses, hospitalizations and disability, which can offset the upfront drug cost in public payer systems.

Strategic role inside Novartis AG

Novartis AG has steadily reshaped its portfolio around patented, higher-margin pharmaceuticals and innovative therapies, and neurology sits among its strategic pillars. Kesimpta contributes to that narrative as a specialty MS product with recurring revenue and a long treatment horizon for eligible patients.

CEO Vasant Narasimhan has repeatedly pointed to targeted immunology and neuroscience as areas where Novartis aims to build durable franchises. Kesimpta’s performance in the US MS market feeds into that strategy, even as the company balances risks tied to competition, pricing pressure, and future generic or biosimilar entrants.

Investor lens and stock context

For retail investors and MS patients alike, Kesimpta is less about quarterly beats and more about the steady shift toward home-based care for complex conditions. Its monthly injection rhythm, high-efficacy profile and specialty pharmacy distribution put it squarely in the center of conversations about how much chronic care can safely move out of hospital settings.

Novartis AG stock (NYSE: NVS, ISIN CH0012005267) reflects a diversified pipeline and portfolio, and the neurology segment, including Kesimpta, forms one part of that broader story without dictating the share price on its own.

Kesimpta at a glance

• Product: Kesimpta (ofatumumab) prefilled autoinjector
• Manufacturer: Novartis AG
• Category: New launch neurology biologic therapy
• Launch: FDA approval August 2020; US rollout from late 2020
• MSRP / Price: Approx. mid-five-figure USD per year in the US before insurance
• Availability: Prescription-only in the US via specialty pharmacies and neurology clinics; also approved in EU and other markets
• Target audience: Adults with relapsing forms of multiple sclerosis needing high-efficacy disease-modifying therapy
• Standout / USP: Self-administered, once-monthly CD20-targeting biologic delivering infusion-level efficacy in a home setting

This article was AI-assisted and editorially reviewed. Product information is provided without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Securities trading carries risks up to total loss.